Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1203560

registered interest
date	15/06/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs
house id	2
legislature	25277 pref label House of Lords
question text	Her Majesty's Government what assessment they have made about whether any drugs or medicines will be in short supply after the UK leaves the EU.
tabling member printed	Lord Roberts of Llandudno
uin	HL5715
answer	answer is ministerial correction date of answer 30/06/2020 answer text <p>The United Kingdom left the European Union on 31 January and is now in a Transition Period until 31 December 2020. During this time, it remains our objective to negotiate a future relationship with the EU and in our respective published negotiating documents, we have both stated objectives to reach an agreement on trade in goods. The UK’s published approach sets out how we want to facilitate trade in medicinal products and support high levels of patient safety.</p><p>The Government, pharmaceutical industry and National Health Service will always work closely together to help ensure patients continue to have access, to the medicines and treatments they need, including insulin, under all scenarios.</p><p>The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the NHS and others in the supply chain to reduce the likelihood of future shortages resulting from any cause.</p><p> </p> answering member printed Lord Bethell grouped question UIN HL5713 question first answered 30/06/2020 15:47:39 answering member 4708 label Biography information for Lord Bethell
tabling member	3691 label Biography information for Lord Roberts of Llandudno

1186624

registered interest
date	19/03/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to manufacture more active pharmaceutical ingredients in the UK to prevent medicine shortages.
tabling member constituency	Coventry North West
tabling member printed	Taiwo Owatemi
uin	32261
answer	answer is ministerial correction date of answer 14/04/2020 answer text <p>The Government has no plans to create facilities in the United Kingdom to manufacture further active pharmaceutical ingredients. There are 16,000 medicines on the market in the UK. Whilst some of these are manufactured in the UK, most are manufactured abroad. Where medicines are manufactured here, the active ingredients and excipients for those medicines may be manufactured abroad. It is not realistic to manufacture all 16,000 medicines and the active ingredients and excipients needed for these medicines in the UK.</p><p>The production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of medicines and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures. These problems arise regardless of where in the world the manufacture takes place.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/04/2020 14:50:24 answering member 4380 label Biography information for Jo Churchill previous answer version 14443 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4779 label Biography information for Taiwo Owatemi

1027714

registered interest
date	18/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer on 11 September to Question number 169109 on Social Care: Drugs, (a) when the 2019-20 planning process was completed and (b) what the level of funding is for the 2019-20 prioritisation process.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	203288
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The independently chaired Clinical Priorities Advisory Group met in November 2018 to make prioritisation recommendations for investments in specialised service for the 2019/20 financial year. Final investment decisions will be announced shortly. A second prioritisation round for investment in 2019/20 will be held next year.</p><p> </p><p>The baseline budget for prioritisation in 2019/20 has been set at £25.7 million reflecting a 2.7% increase on the 2018/19 budget. The availability of any additional funding to support prioritisation will be kept under review between now and May/June 2019 when the second round of investment decisions will be taken for the 2019/20 financial year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2018 15:58:15 answering member 4067 label Biography information for Steve Brine
tabling member	1383 label Biography information for Mark Tami